Following a full submission, the Scottish Medicines Consortium (SMC) has accepted tafluprost preservative-free eye drops (Saflutan™) for restricted use within NHS Scotland for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension:

• as monotherapy: in patients who would benefit from preservative-free eye-drops, who are insufficiently responsive to first-line therapy, or who are intolerant or contraindicated to first-line therapy
• or as adjunctive therapy to beta-blockers

Tafluprost is restricted to use in patients who cannot tolerate currently available prostaglandin preparations due to proven sensitivity to the preservative benzalkonium chloride.  Saflutan is the only preservative-free prostaglandin eye drop available.